DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "World Parkinsons disease Drug Market - Opportunities and Forecasts, 2014 -2022" report to their offering.
According to the Parkinson's Disease Foundation, there are about 10 million people suffering from Parkinson's disease globally. Parkinson's, in terms of its presence, has a higher frequency in the developed countries. In the United States (U.S.), around 60,000 new cases are diagnosed with Parkinson's, each year. Parkinson's disease is an idiopathic disease occurring due to unknown causes. Presently, only symptomatic drug treatments are available in the market. Moreover, these symptoms are diagnosed at later stages when most of the dopamine producing cells have lost their function. This scenario indicates an impending need for innovative drugs.
Rising old age population and higher incidences of neurodegenerative diseases are two significant factors that drive the growth of this market. Moreover, increasing R&D investment and number of drugs in the pipeline are further expected to fuel the market growth. However, high cost of treatment and lack of expertise for early diagnosis is likely to curtail the market growth.
The global Parkinson's disease market is segmented on the basis of drug type and geography. According to drug type, the market is segmented into, marketed and pipeline drugs. The marketed drugs are further segmented into Levodopa, Dopamine agonists, Apomorphine, Glutamate antagonist, Anticholinergics, COMT inhibitors and MAO-B inhibitors. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific, and LAMEA.
Key Market Segments:
The global Parkinson's disease market is segmented below:
Parkinson's Disease Market - By Drug Type
- Marketed Drugs
- Levodopa
- Dopamine agonists
- Apomorphine
- Glutamate antagonist
- Anticholinergics
- COMT inhibitors
- MAO-B inhibitors
-
Pipeline Drugs
Parkinson's Disease Market - By Geography
- North America
- Europe
- Asia-Pacific
-
LAMEA
For more information about this report visit http://www.researchandmarkets.com/research/47fcdh/world_parkinsons
